Is NCT06088888 recruiting in Houston, TX?

Yes, NCT06088888 is currently recruiting participants at its Houston, TX location. This chronic myelogenous leukemia clinical trial is actively enrolling qualified participants.

How do I join the chronic myelogenous leukemia clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chronic Myelogenous Leukemia Clinical Trial in Houston, TX

About This Chronic Myelogenous Leukemia Study in Houston

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Sponsor: Shenzhen TargetRx Co., Ltd.

Who Can Participate

Inclusion Criteria

Willing to participate in the study with informed consent;

At least 18 years of age at the time of screening;

Diagnosis of CML-CPduring the screening period;

Intolerant or resistant to TKI treatments;

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;

Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels;

Adequate renal and liver function;

Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results;

Negative blood pregnancy test results for female patients of childbearing potential.

Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.

Exclusion Criteria

Exposure to other antineoplastic therapies prior to study enrollment;

Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy;

Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia);

Hematopoietic cell transplantation \< 60 days prior to the first dose;

Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy;

Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment);

Exposure to drugs related to torsade de pointes;

Cytological or pathological diagnosis of active central nervous system disorder;

Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol;

Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome;

Uncontrolled hypertension;

Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose;

Severe hemorrhagic disorders unrelated to CML;

History of pancreatitis;

History of excessive alcohol use;

History of elevation in amylase or lipase within 1 year;

Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening;

Uncontrolled hypertriglyceridemia;

Malabsorption syndrome or other illness that could affect oral absorption.

Diagnosis of another primary malignancy in the past 3 years;

Reception of major surgery within 14 days prior to the first dose;

Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment;

Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections);

Have received or will receive a COVID-19 vaccine within 14 days of study enrollment;

Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening;

Pregnant or breastfeeding female;

Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug;

Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor;

Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06088888) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Myelogenous Leukemia Treatment Options in Houston, TX

If you're searching for chronic myelogenous leukemia treatment options in Houston, TX, this clinical trial (NCT06088888) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic myelogenous leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic myelogenous leukemia clinical trials near you to find additional studies recruiting in your area.

Chronic Myelogenous Leukemia Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process